Primary intracranial dural lymphoma of mucosa-associated lymphoid tissue (MALT) type: report of one case and review of the literature.
Détails
ID Serval
serval:BIB_D234D3407DDA
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Primary intracranial dural lymphoma of mucosa-associated lymphoid tissue (MALT) type: report of one case and review of the literature.
Périodique
Bulletin du Cancer
ISSN
1769-6917 (Electronic)
ISSN-L
0007-4551
Statut éditorial
Publié
Date de publication
07/2005
Volume
92
Numéro
7
Pages
E51-E56
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
Primary indolent leptomeningeal lymphoma is a rare entity, and corresponds in most cases to mucosa-associated lymphoid tissue (MALT) type lymphoma. We are reporting a case of a 75 years old woman, who presented with a 2-year history of behavioral disorder, progressive memory loss and aphasia. Neuroimaging showed a mass infiltrating the frontal circumvolutions and the roof of the orbit. The biopsy revealed an infiltration of the dura by an indolent lymphoma, characteristic of a MALT-type lymphoma. Complete staging work-up did not show any evidence of systemic involvement. A treatment with systemic methotrexate, combined with intrathecal chemotherapy and followed by radiotherapy (30,6 Gy) of the primary site, was conducted. The 3-year follow-up confirms the persistent remission, the patient remaining well and free of symptoms. The review of the literature highlights the importance to recognize the indolent PLML as a distinct clinical entity, which exhibits a rather good prognosis following a relatively non-toxic therapy.
Mots-clé
Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Combined Modality Therapy, Cytarabine/administration & dosage, Dura Mater, Female, Humans, Hydrocortisone/administration & dosage, Lymphoma, B-Cell, Marginal Zone/cerebrospinal fluid, Lymphoma, B-Cell, Marginal Zone/pathology, Meningeal Neoplasms/cerebrospinal fluid, Meningeal Neoplasms/pathology, Methotrexate/administration & dosage
Pubmed
Création de la notice
08/04/2008 15:48
Dernière modification de la notice
20/08/2019 16:52